Perimenopause Is Inevitable. Suffering Is Not.
How decades of misunderstanding left millions of women untreated—and why the evidence now supports a different approach.
Perimenopause remains one of the most common, underdiagnosed, and undertreated conditions in medicine, and it is time for the medical community to fully correct its course.
For decades, women have been told their symptoms were stress, depression, burnout, or simply part of aging. Many were prescribed antidepressants, sleep medications, or told nothing was wrong at all.
Meanwhile, the underlying issue was often hormonal.
Commonly Overlooked Perimenopause Symptoms
While hot flashes are the most widely recognized symptom (71% awareness), the most commonly experienced symptoms tell a different story. Women aged 35+ most frequently report fatigue (83%), physical and mental exhaustion (83%), irritability (80%), depressive mood (77%), sleep problems (76%), digestive issues (76%), and anxiety (75%). Notably, fatigue, headache, anxiety, and brain fog are very common across all reproductive life stages, yet limiting focus to vasomotor symptoms neglects a large proportion of overall symptom burden. These mood and cognitive symptoms often interact with one another — depressed women tend to experience worse hot flashes and worse sleep.
Proven Benefits of HRT
The evidence strongly supports the following benefits:
Vasomotor symptoms: HRT reduces hot flash frequency by approximately 75% compared to placebo — the most effective treatment available.
Genitourinary syndrome of menopause: Effective for vaginal dryness and dyspareunia.
Osteoporotic fracture prevention: Combined HRT reduces all clinical fractures by 22% (230 fewer fractures per 10,000 women over 5 years); estrogen-only therapy reduces fractures by 27% (388 fewer per 10,000 women over 7.2 years).
Diabetes prevention: Estrogen-only therapy reduces diabetes incidence by 134 cases per 10,000 women over 7.1 years; combined therapy reduces it by 78 cases per 10,000 over 5.6 years.
Colorectal cancer: Combined estrogen-progestin therapy reduces colorectal cancer by 34 cases per 10,000 women over 5.6 years.
Sleep quality: Small but statistically significant improvements in sleep, particularly when treating vasomotor symptoms.
Likely Benefits Requiring More Evidence
The following benefits show promise but need additional research:
Cardiovascular protection in younger women: Age-stratified analyses suggest more favorable effects on coronary heart disease and all-cause mortality in women who start HRT close to menopause (under age 60 or within 10 years of menopause onset), supporting the "timing hypothesis."
Cognitive function: HRT may improve memory and concentration in women taking it for vasomotor symptoms, but is unlikely to have effects in women without vasomotor symptoms.
Breast cancer reduction with estrogen-only therapy: Long-term follow-up from the WHI showed statistically significant breast cancer risk reduction at 13 and 20.7 years with estrogen-only therapy, though this was not significant during the intervention phase.
Overall mortality reduction: A nonsignificant trend toward reduced mortality has been observed with estrogen therapy, particularly in younger women.
Important Context
The risk-benefit profile differs significantly between estrogen-only and combined estrogen-progestin therapy, and varies by age at initiation, time since menopause, and individual health status. For healthy women who begin HRT soon after menopause, benefits likely outweigh harms, particularly for symptom control and quality of life.
References
Aras SG, Grant AD, Konhilas JP. Clustering of >145,000 Symptom Logs Reveals Distinct Pre, Peri, and Menopausal Phenotypes. Scientific Reports. 2025;15(1):640.
Hedges MS, et al. Global Perspectives on Perimenopause: A Digital Survey of Knowledge and Symptoms Using the Flo Application. Menopause. 2026.
Santoro N, et al. The Menopause Transition: Signs, Symptoms, and Management Options. J Clin Endocrinol Metab. 2021;106(1):1-15.
Duralde ER, Sobel TH, Manson JE. Management of Perimenopausal and Menopausal Symptoms. BMJ. 2023;382:e072612.
Santoro N. Perimenopause: From Research to Practice. J Womens Health. 2016;25(4):332-9.
Crandall CJ, Mehta JM, Manson JE. Management of Menopausal Symptoms: A Review. JAMA. 2023;329(5):405-420.
Genazzani AR, et al. Hormone Therapy in the Postmenopausal Years. Human Reproduction Update. 2021;27(6):1115-1150.
Flores VA, Pal L, Manson JE. Hormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment. Endocrine Reviews. 2021;42(6):720-752.
Gartlehner G, et al. Hormone Therapy for Primary Prevention of Chronic Conditions in Postmenopausal Persons. JAMA. 2022;328(17):1747-1765.
Bofill Rodriguez M, et al. Long-Term Hormone Therapy for Perimenopausal and Postmenopausal Women. Cochrane Database Syst Rev. 2025;11:CD004143.
Hickey M, et al. An Empowerment Model for Managing Menopause. Lancet. 2024;403(10430):947-957.
